Adrenal Medullary Transplants as a Treatment for Advanced Parkinson’s Disease
It is no coincidence that human neural transplantation currently focuse on Parkinson’s Disease. In PD, of all the neurodegenerative disorders, there is the clearest relationship between the pathology [the loss of catecholamine containing pigmented neurons in the substantia nigra pars compacta (SNpc)], the neurochemistry [the loss of striatal dopamine (DA)] the pathophysiology (the disinhibition of the striatum), and the clinical symptoms. Moreover, the loss of tissue in PD is small and restricted to the SNpc. It was reasonable to expect that if a transplant could substitute for the lost SNpc neurons in patients with PD, then symptoms might improve.
KeywordsTyrosine Hydroxylase Caudate Nucleus Neuroleptic Malignant Syndrome Vocal Cord Paralysis Adrenal Tissue
Unable to display preview. Download preview PDF.
- 2.Lieberman A (1987) Update on Parkinson disease. NY State J Med 87: 147 – 153Google Scholar
- 5.Olson L, Blacklund EO, Gerhardt G (1986) Nigral and adrenal grafts in parkinsonism. Recent basis and clinical studies. Adv Neurol 454: 85 – 94Google Scholar
- 8.Freed WJ, Morihisa JM, Spoor E (1981) Transplanted adrenal chromaffin cells in rat brain reduce lesion induced rotational behaviour. Nature 2292: 350 – 351Google Scholar
- 13.Fahn S, Elton RL (1988) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent development in Parkinson’s disease. Macmillan, New York, pp 153 – 163Google Scholar